ARCH Venture led a $85m Series A round in Epirium Bio, a clinical stage biopharmaceutical company, with participation from Longitude Capital, Bluebird Ventures, Adams Street Partners, Vertex Ventures HC, and The Longevity Fund. "We are thrilled to partner with an exceptional team of visionary and highly respected investors, who have a strong track record in uncovering and backing only the most promising science. I look forward to leading a very experienced management team as we advance the application of the unique biology we have discovered, which has already produced promising signals of clinical benefit," Russell Cox, Epirium President and CEO.